All News
Challenge in Measuring Cutaneous Lupus Activity and Severity
JAMA Dermatology features a discussion by Drs. McMichael and Frey on measuring lupus skin disease in clinical trials and practice using the validated Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI).
Read Article
ICYMI: Reproductive Issues in axSpA: Fertility and Pregnancy
Axial spondyloarthritis (axSpA) affects young patients with symptom onset occurring in early adulthood. Apart from pain and quality of life, reproductive issues also arise because patients who are diagnosed with the disease are also in their reproductive age. Two interesting abstracts about reproductive issues in axSpA will be presented during the poster sessions on Saturday, November 16, 2024.
Read Article
Inebilizumab for Treatment of IgG4-Related Disease
Inebilizumab is an monoclonal antibody that targets and depletes CD19+ B cells and has been studied in adults with IgG4-related disease.
Phase 2b Study of Ianalumab in Sjögren's
A 52-week has demonstrated the safety and efficacy of ianalumab, a dual B cell depleter) in patients with active Sjögren's disease (SjD).
JAMA Images in Dermatology - Palmar Fasciitis and Polyarthritis Syndrome -- 50yoM w/ 6 mo. hx of hand/finger swelling, stiffness, thickening, and erythema, impairing mobility. Also found to have hepato-/splenomegaly, WBC 151K, LDH 889; abnl BM Bx. Pt dx w/ palmar fasciitis & CML… https://t.co/1Z9Oz0sRa7 https://t.co/HRSJcv4lzZ
Dr. John Cush RheumNow ( View Tweet)
Full Read Review of the Pulmonary Manifestations in Antisynthetase Syndrome (good reference!) https://t.co/gBLYRmHKE4 https://t.co/pUWmQCHk0N
Links:
Dr. John Cush RheumNow ( View Tweet)
JAMA Patient Quiz - Joint Pain in a Woman Wearing a Face Mask https://t.co/fbUERrmzW4 https://t.co/KMJZqsSyMG
Dr. John Cush RheumNow ( View Tweet)
BMJ has published an extensive, full read review of the Advances in the management of psoriatic arthritis in adults - by Drs. Gladman and Kharouf, (great read and reference!) https://t.co/21SHvGyUZH https://t.co/grDr5mfAzn
Dr. John Cush RheumNow ( View Tweet)
Treat-to-Target Improves Fertility in Women with RA
https://t.co/q9IMI5UHGO https://t.co/uhqaRXeBRX
Dr. John Cush RheumNow ( View Tweet)
JAMA FULL READ review and overview of Axial Spondyloarthritis by Drs. Deodhar & Bittar
- Dx often delayed 6-8 yrs
- Sensitivity/Specificity of: HLA-B27 (50%/90%), CRP (35%/91%), Xray sacroiliitis (66%/68%) or MRI (78%/88%). Great tables, figs, Xrays &Reference!… https://t.co/MWpznXqPzq https://t.co/46BkH4x9eE
Dr. John Cush RheumNow ( View Tweet)
Fibroblastic Rheumatism - JAMA Case: 50yoM w/ 3 yr hx of periarticular nodules, symmetric polyarthralgia at B/L PIPs. These were painful with manipulation or minor trauma. Labs negative. https://t.co/FeLH1GIHr9 https://t.co/Pj1FRHj25u
Dr. John Cush RheumNow ( View Tweet)
Biologic Monotherapy vs Combination with cDMARDs in PsA
https://t.co/MfqyD6hyOK https://t.co/fRJjOaJ9aT https://t.co/z8gutP79Ub
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Shifting Trends in Initial RA Treatment Approaches
A recent study by Sparks et al (Abstract #0509) reveals evolving trends in disease-modifying antirheumatic drug (DMARD) usage for RA over two decades in the US.
https://t.co/XlMXkuBBVN https://t.co/AHi3DG0aFV https://t.co/vNLF4Ft1GR
Links:
Dr. John Cush RheumNow ( View Tweet)
DEA and the Department of Health and Human Services (HHS) has extended current telemedicine (TM) flexibilities through end 2025. MDs may Rx meds via TM (including narcotics) without in-office visits. https://t.co/C8lyB5feXg https://t.co/eSjYCnu02Y
Dr. John Cush RheumNow ( View Tweet)
ACR24 IL-17 Topic Panel: Advancing Care with IL-17 Pathway Insights https://t.co/t9QQDYIrda
Links:
Dr. John Cush RheumNow ( View Tweet)
#ACR24: Rheumatology Roundup
https://t.co/0DMcpsAZce https://t.co/JvMnfAt3EP
Dr. John Cush RheumNow ( View Tweet)
Diagnostic Delays in PsA
Despite the remarkable expansion of the therapeutic armamentarium for psoriatic arthritis (PsA), the MONITOR-PsA study (abstract 1456) highlights a persistent and critical issue: delays in diagnosis.
https://t.co/83TeIpfutP https://t.co/85qo7F9IPa
Dr. John Cush RheumNow ( View Tweet)
Off-Label Use of JAK Inhibitors in Orphan Diseases and Other Conditions?
The issues surrounding publication bias are real.
https://t.co/gIFNjAsoM6 https://t.co/UstQGvJX7H
Dr. John Cush RheumNow ( View Tweet)
UK study compared 16,634 female RA pts vs 65,448 controls and found all RA women at incr risk for VTE (thrombosis)[aHR=1.52) irrespective of estrogen contraceptives/HRT. Contraceptives did not increase VTE risk (aHR 2.32; 0.92, 5.85, p=0.08) #ACR24 https://t.co/AzBXI0W5dv https://t.co/Q4TaKq2ReC
Dr. John Cush RheumNow ( View Tweet)
Osteoarthritis (OA) affects 53.2 million in the USA & is projected to rise significantly by 2040. Societal costs are $132 billion ($11,00 per/pt). OA is the 3rd most rapidly rising disability, behind diabetes and dementia. https://t.co/n3Rwjjsio3 https://t.co/FPDWd6gEpi
Dr. John Cush RheumNow ( View Tweet)